Investigational drug · Phase 2
ETX101
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dravet Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "ETX101"
First trial start
2024
Feb 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ETX101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dravet Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ETX101" as an intervention, largest first.
- A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromePivotal-lookingRecruiting
Encoded TherapeuticsIndustry
NCT05419492 · 113 participants (planned) · Start May 14, 2024 · Primary completion Jun 2028
Drug: ETX101 · For: Dravet Syndrome
Sites: San Francisco, California; Aurora, Colorado; Miami, Florida · 14 sites in all
- A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet SyndromeActive, not recruiting
Encoded TherapeuticsIndustry
NCT06283212 · 5 participants · Start May 9, 2024 · Primary completion Oct 2030
Drug: ETX101 · For: Dravet Syndrome
Sites: Glasgow, United Kingdom; London, United Kingdom; Sheffield, United Kingdom
- A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)Active, not recruiting
Encoded TherapeuticsIndustry
NCT06112275 · 4 participants · Start Feb 28, 2024 · Primary completion Sep 2030
Drug: ETX101 · For: Dravet Syndrome
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Voltage-gated sodium channels in the nervous system: Molecular physiology to therapeutic interventions.
Li N, Yan L, Peng A, et al. · Neural Regen Res 2026
- Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
Balestrini S, Scheffer IE · CNS Drugs 2026
- Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies.
Samanta D, Bhatia S, Hunter SE, et al. · Pediatr Neurol 2025
- Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development.
Bialer M, Johannessen SI, Koepp MJ, et al. · Epilepsia 2024
- Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome.
Lersch R, Jannadi R, Grosse L, et al. · Neuroscientist 2023
Also in development for Dravet Syndrome
- LP352bexicaserinPhase 34 trials
Longboard Pharmaceuticals · Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Clemizole HClEPX-100Phase 32 trials
Epygenix · Dravet Syndrome, Lennox Gastaut Syndrome
- zorevunersenSTK-001Phase 32 trials
Stoke Therapeutics, Inc · Dravet Syndrome
- BMB-101Phase 22 trials
Bright Minds Biosciences Pty Ltd · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome
- ION337Phase 21 trial
Ionis Pharmaceuticals · Dravet Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.